If your facility has ever had a clean-looking claim get denied for no obvious reason, there is a good chance a pharmacy line item was the culprit. Revenue Code 636 is one of those codes that looks simple on the surface but causes real financial damage when a biller misses one small requirement.
This guide breaks down exactly what Revenue Code 636 means, where it applies, how Medicare, Medicaid, and commercial payers reimburse it in 2026, and the specific mistakes that turn a payable drug claim into a rejected one.
Quick Answer: What Is Revenue Code 636?
Revenue Code 636 (also written as 0636) is the National Uniform Billing Committee code for "Pharmacy: Drugs Requiring Detailed Coding." It is used on UB-04 institutional claims to report drugs and biologicals that must be identified with a specific HCPCS code, rather than billed as a general pharmacy charge. On inpatient claims, its use is far narrower, limited almost entirely to hemophilia clotting factor billing.
What Revenue Code 636 Actually Covers
Revenue codes tell a payer which department or cost center generated a charge. Where a CPT or HCPCS code says what was done, the revenue code says where it happened and how it should be categorized for payment. Revenue Code 636 exists specifically for the subset of pharmacy charges that cannot be safely bundled into a flat rate because the drug's cost varies too much to guess at.
Two separate rules apply depending on the setting, and mixing them up is where most confusion starts.
| Setting | How Revenue Code 636 Is Used |
|---|---|
| Inpatient (Medicare) | Reserved almost exclusively for hemophilia clotting factor billing, reported with the matching HCPCS code and billing units based on 100 IU per unit. |
| Outpatient (Medicare, Medicaid, commercial) | Used broadly for any drug that requires detailed HCPCS-level identification, including injectables, biologics, and chemotherapy agents. |
| Home Health Agency (bill type 34X) | Used when reporting a vaccine's drug cost alongside revenue code 771 for the administration charge, under the Medicare home health vaccine benefit. |
| Physician office (CMS-1500) | Not applicable. Revenue codes only exist on institutional/facility claims. |
That HHA vaccine-billing use case is one that a lot of guides skip entirely, but it matters if your organization handles home health claims: the drug itself goes under 636, and the administration is billed separately under 771, with no combined charge for the visit.
Inpatient vs Outpatient: Why the Distinction Matters So Much
On inpatient claims, drug costs are almost always folded into the DRG (Diagnosis Related Group) payment. The DRG rate is meant to cover the entire stay, medications included, so billing a drug separately under Revenue Code 636 on an inpatient claim will usually be denied as a duplicate charge.
The one long-standing exception is hemophilia clotting factor. Because these products are extraordinarily expensive and variable in dose, CMS carved out a specific inpatient billing pathway: report the HCPCS code for the clotting factor, with each 100 IU counted as one billing unit. If the total units administered exceed the field limit on a single line, the excess is reported as a second line using the same revenue code and HCPCS code.
Beyond clotting factor, a small number of pass-through drugs or CMS-excluded items may still qualify for separate inpatient billing, but these are rare and should be verified against current payer policy before submission, not assumed.
Outpatient is where Revenue Code 636 does most of its work. Hospital outpatient departments, infusion centers, and emergency departments use it for any drug that carries its own HCPCS J-code, Q-code, or C-code and needs individual pricing rather than a bundled visit rate.
How Reimbursement Actually Works in 2026
Reimbursement is not a flat number. It depends on the payer, the drug's payment status, and how completely the claim line was built.
Medicare (OPPS)
Medicare pays through the Outpatient Prospective Payment System, and the deciding factor is the Status Indicator CMS assigns to each drug in its quarterly Addendum B release.
| Status Indicator | What It Means | Payment Outcome |
|---|---|---|
| K | Separately payable drug | Paid at ASP + 6% |
| G | Pass-through drug (temporary) | Paid at cost during the pass-through period |
| N | Packaged into the APC | No separate payment |
| E2 | Non-covered under OPPS | No Medicare payment |
For calendar year 2026, CMS set the drug packaging threshold at $140 per day. Any drug with a per-day cost at or below that figure is generally packaged into the visit payment and will not generate a separate line payment under Revenue Code 636, regardless of how correctly the claim is built. Anything above that threshold is eligible for separate reimbursement. Since this figure is adjusted annually, a claim built on last year's assumptions can quietly under-bill or over-bill without anyone noticing until an audit.
Medicaid
Medicaid reimbursement varies by state, but a few patterns hold almost everywhere:
- Each drug typically needs its own 636 line paired with a HCPCS code
- Most states price at Average Sales Price, though some still use AWP-based formulas
- The 11-digit NDC is required on nearly every state's drug claim lines, partly because states use NDC data to calculate manufacturer drug rebates
A missing NDC on a Medicaid drug claim is one of the most common, and most avoidable, causes of denial.
Commercial Payers
There is no universal rulebook here. Reimbursement is governed entirely by the contract language your facility negotiated with each payer. Some follow Medicare's ASP methodology, others use AWP minus a negotiated discount, and a growing number now require NDCs on every high-cost drug line regardless of HCPCS specificity. The only reliable approach is reading the pharmacy billing provisions in each contract directly rather than assuming Medicare rules apply.
When to Use Revenue Code 636
- Injectable drugs given in an outpatient department, infusion center, or ED that carry their own HCPCS J-code or Q-code
- Biologics such as monoclonal antibodies, immunomodulators, and biosimilars that need line-item identification because their cost is too high to absorb into a flat rate
- Chemotherapy and antineoplastic agents administered in hospital outpatient settings
- Any drug CMS has assigned a Status Indicator of K or G in the current OPPS release
- Vaccines billed by home health agencies under bill type 34X, paired with revenue code 771 for administration
- Drugs that require NDC-level reporting for payer compliance, including Not Otherwise Classified codes like J3490
When Not to Use Revenue Code 636
- Routine pharmacy items such as saline flushes, oral ED medications, or standard IV hydration fluids belong under Revenue Code 250, not 636
- Medications already bundled into an inpatient DRG payment
- Any drug line submitted without a matching HCPCS code in Form Locator 44; this alone triggers an automatic denial
- Take-home medications, which usually fall under a different revenue code such as 253
- Supplies and administration materials like IV bags or tubing, since these are not drugs at all
Revenue Code 636 vs 250: The Comparison Billers Actually Need
| Factor | Revenue Code 250 | Revenue Code 636 |
|---|---|---|
| Official description | Pharmacy: General Classification | Pharmacy: Drugs Requiring Detailed Coding |
| HCPCS required | Sometimes | Always |
| NDC required | Depends on payer/state | Usually, especially Medicaid and commercial |
| Specificity | Department-level | Line-item, exact drug and dose |
| Typical use | Routine, low-cost medications | High-cost injectables, biologics, chemo |
| Medicare OPPS treatment | Usually packaged | Separately payable when status is K or G |
The decision rule is simple: if the drug needs HCPCS-level identification and is billed for separate reimbursement, it goes under 636. If it is a routine charge the payer will bundle regardless, 250 is correct.
UB-04 Field-by-Field Walkthrough
| Form Locator | Field | What Goes There |
|---|---|---|
| FL 42 | Revenue Code | 0636 on each applicable drug line |
| FL 43 | Description | Drug name, e.g. "Inj, Rituximab" |
| FL 44 | HCPCS/Rate | The specific J-code, Q-code, or C-code. Leaving this blank causes automatic denial |
| FL 45 | Service Date | Exact administration date; never batch multiple dates on one line |
| FL 46 | Service Units | Billing units as defined by the HCPCS description, not the number of vials used |
| FL 47 | Total Charges | Facility charge master rate for that line |
Units matter more than most billers realize. If a HCPCS code defines 1 unit as 10mg and the patient received 50mg, the line should show 5 units, not 1 vial. Billing by vial count instead of the defined unit is a quiet way to capture a fraction of the reimbursement you actually earned.
Converting NDC to the Standard 11-Digit Format
Drug packaging prints NDCs in varying segment lengths, but claims require the 5-4-2, 11-digit format.
| Package Format | Conversion |
|---|---|
| 4-4-2 (e.g. 1234-5678-90) | Add a leading zero to the labeler segment: 01234-5678-90 |
| 5-3-2 (e.g. 12345-678-90) | Add a leading zero to the product segment: 12345-0678-90 |
| 5-4-2 (e.g. 12345-6789-01) | Already correct, no conversion needed |
Most clearinghouses strip hyphens automatically, but it is worth confirming rather than assuming.
Why Revenue Code 636 Claims Get Denied
Most 636 denials trace back to one of four root causes:
- Missing HCPCS code — the revenue code signals "detailed identification incoming," and an empty FL 44 leaves the payer with nothing to price
- Missing or malformed NDC — especially costly on Medicaid claims, where rebate calculation depends on accurate NDC reporting
- Wrong billing units — reporting vials or packages instead of the HCPCS-defined unit
- Setting mismatch — billing an inpatient DRG-bundled drug separately, or using 636 for a routine charge that belongs under 250
Building a pre-submission check for these four points catches the majority of preventable pharmacy denials before a claim ever reaches the payer. If denials are already a recurring issue at your facility, it's worth looking at your broader claim denial prevention process rather than fixing this one code in isolation.
Frequently Asked Questions
Does Revenue Code 636 require an NDC?
For Medicare fee-for-service, generally no, since the HCPCS code alone identifies and prices the drug. Medicare Advantage plans often differ, though. Medicaid almost universally requires it. Commercial payers increasingly require it for high-cost drugs, particularly on Not Otherwise Classified codes like J3490.
Can Revenue Code 636 be used on inpatient claims?
Rarely, and mainly for hemophilia clotting factor or specific CMS-excluded pass-through drugs. Standard inpatient drug costs are covered under the DRG payment and cannot be billed separately.
What is the difference between Revenue Code 636 and 250?
636 is for drugs that require HCPCS-level detail and are billed for separate reimbursement. 250 is the general pharmacy category for routine, lower-cost medications that are typically bundled into the visit rate.
What happens if a 636 line is submitted without a HCPCS code?
The claim is treated as incomplete for that line and is typically denied or returned as unprocessable, since the payer has no way to price the drug.
Does the drug packaging threshold change every year?
Yes. CMS adjusts it annually using Producer Price Index data. It moved from $135 in 2025 to $140 in 2026 for most drugs, and the diagnostic radiopharmaceutical threshold moved to $655.
Struggling With Recurring Pharmacy Claim Denials?
Every denied 636 line is revenue your facility already earned but hasn't collected. Our revenue cycle management and medical coding teams review payer-specific pharmacy billing rules, HCPCS and NDC accuracy, and unit calculations, so high-cost drug claims like hemophilia factor, chemotherapy, and specialty biologics get paid the first time. Specialty programs such as hematology and oncology billing get particular attention, since these are the claims where 636 errors cost the most.
Struggling With Recurring Pharmacy Claim Denials?
Every denied 636 line is revenue your facility already earned but hasn't collected. Our teams review payer-specific pharmacy billing rules, HCPCS and NDC accuracy, and unit calculations, so high-cost drug claims get paid the first time.
ClainetRCM Billing Team
ClainetRCM is a Boston-based revenue cycle management company specializing in medical billing, coding, and denial management for healthcare providers across all 50 states. Our AAPC and AHIMA certified coders track every ICD-10-CM update so claims go out coded to the current fiscal year's release.